ALI HEALTH (00241) saw its shares climb more than 4%. As of the time of writing, the stock was up 3.78% to HKD 6.86, with a trading volume of HKD 532 million. On the news front, it was reported on January 19 that ALI HEALTH's significant AI product, "Qing Lizi" (Hydrogen Ion), has completed its internal testing phase and is now available for public download. It is understood that the product has already moved into practical application, primarily targeting physicians in clinical and scientific research fields. "Qing Lizi" emphasizes its core capabilities of "low hallucination, high evidence-based" performance, with all responses backed by authoritative sources, supporting one-click traceability to the original information, aiming to create the AI assistant with the lowest hallucination rate in the medical field. Feedback from multiple doctors who participated in the internal test indicated that "Qing Lizi" demonstrates high accuracy in tasks such as evidence-based Q&A, evidence integration, and analytical summarization, particularly excelling in intelligent retrieval and the review of Chinese and English literature within clinical and research contexts, which aligns well with the habits of domestic physicians. Its product logic is similar to the highly popular overseas product OpenEvidence, but it holds an advantage in terms of localized user experience.